Nico.lab will attend the 2017 AHA International Stroke Conference from February 22th until February 25th at the George Brown Convention Center in Houston, Texas. Come visit us for a live demo at Booth 703 in the Exhibition Hall (D).
Nico.lab has successfully won the bid for a tender issued by international pharmaceutical company Bayer. For the coming three years, Nico.lab will act as the core lab for the project and coordinate the collection of data from 15 sites in Germany, providing them with standard operating procedures and managing the transfer of imaging data. Nico.lab will then employ its own expertise and technology to process and analyse the data from over 600 patients. The trial, which is part of a larger project investigating a new treatment for aortic valve replacement, will assess which compounds are most effective in preventing cerebral infarction after valve replacement. Nico.lab's technology is a valuable tool in trials of this nature.
Only several weeks after being appointed a €50,000 European grant, we are excited to announce that we have successfully presented to Amsterdam Innovation Exchange to receive a €100,000 pre-seed loan, and to technology foundation STW to receive a €40,000 grant. The pre-seed loan will be used to further develop our proof of concept by widening the portfolio of automated computer vision tools, and the grant from STW will be used for business development. Our toolbox assists radiologists in the diagnosis and treatment selection for stroke patients, and as such has the potential to impact the lives of many.
Horizon 2020 SME granted to AMC spin-off Nico.Lab for automated quantitative image analysis in acute ischemic stroke patients
As part of the highly successful MR CLEAN trial, the image analysis group of the Biomedical Engineering and Physics department at AMC, University of Amsterdam (www.amc.uva/bmep), developed a portfolio of automated computer vision tools. These tools enable quantitative analyses of radiological images taken from patients suspected of having ischemic stroke. The value of these tools has been recognized worldwide with requests to utilize them in a wide range of studies and research groups.
This success prompted the creation of spin-off company Nico.lab that will professionalize and commercialize the automated analysis tools for a broader audience. The commercial potential was acknowledged by the Horizon 2020 program for highly-innovative Small and Medium-sized Enterprises to support growth and expanding activities. This program is very competitive with fewer than 3% of the applications being awarded. Nico.lab is very proud to be considered for the further development of groundbreaking innovative products and services.
We congratulate the AMC Neurovascular research group for having their study on the dynamic and 3D analysis of intra-aneurysmal vorticity published. This paper is another important step in the automated and objective analysis of neurovascular disease. Nico.lab is planning to provide this analysis as part of their service in the near future.
MR CLEAN Dutch RANDOMIZED CLINICAL trial on intraarterial treatment published in new England journal of medicine
Nico.lab congratulates the MRCLEAN investigators with the first positive intra-arterial treatment RCT! “We are very proud to have been able to support this trial, and we are pleased to learn that quantitative infarct volume is indeed a valuable outcome measure”